The Senate Appropriations Committee's three-bill FY26 Commerce-Justice-Science package sets the National Science Foundation at $8.75 billion — $7.18 billion for research and related activities supporting nearly 10,000 new awards and 250,000-plus scientists. [1] On the same calendar, the Trump administration's late-April disbandment of the National Science Board enters its eleventh day with no replacement nominees, no acting board, and no response from the academy to the Senate Commerce Committee's antideficiency-letter from Senator Whitehouse. The May 4 paper's account of the National Science Board Day Ten arriving with Whitehouse ADA Day Ten holding recorded the 24-hour window. Day 11 inherits the silence.

The Senate floor and the executive disbandment are now moving in opposite directions. Both registers operate under the same statutory framework — the National Science Foundation Act of 1950 — and both treat the foundation as central to U.S. research infrastructure. The two registers diverge on what governs NSF day-to-day. The Senate restores funding through normal appropriations process. The administration treats the board as constitutionally defective and the foundation's senior leadership as eligible for replacement.

Inside Higher Ed reported Monday that prior NSF heads — including former directors France Córdova, Sethuraman Panchanathan, and Subra Suresh — published an open letter calling for immediate appointments to the National Science Board and for nomination of a permanent NSF director. [2] The letter's signatories represent more than a half-century of NSF leadership across administrations of both parties. The argument is not partisan; it is institutional. The NSF cannot operate its grant-making, merit-review, and program-management functions under the dual condition of an unstaffed governing board and a vacant directorship. The letter constitutes the strongest external pressure on the disbandment to date.

The administration's stated rationale for disbanding the board cites US v. Arthrex (2021), the Supreme Court's appointments-clause decision concerning Patent Trial and Appeal Board judges. Arthrex held that PTAB judges, who exercised significant agency authority without principal-officer accountability, were appointed in violation of the Appointments Clause. [3] The administration's analogy applies the same reasoning to NSB members, who under current statute serve six-year terms staggered to insulate the board from short-term political pressure. House Science ranking member Zoe Lofgren has rejected the analogy: NSB members are scientists making program-level judgments under congressionally specified criteria, not adjudicators issuing binding decisions.

The argument that the disbandment is constitutional is not the same argument as the argument that the disbandment is necessary. The administration could have proposed legislative fixes — converting NSB members to advisory rather than principal status, restructuring the board's authorities to fit Arthrex's framework, or transferring the board's existing functions to the director's office under direct presidential supervision. None of these has been proposed. The disbandment proceeded by withdrawal of recess appointments and refusal to nominate replacements, leaving the board statutorily intact but functionally empty.

The May 4 paper noted the contrast with the Joint Committee on Vaccination and Immunisation's 96-hour Anders-Dale succession in the United Kingdom — a foreign committee that lost its chair to a heart attack and produced a successor in four days. NSF Day 11 reads against the JCVI's Day 4 as a continuity-test the U.S. institution is failing under conditions the U.K. institution managed under a more difficult precipitating event. The contrast is not about the relative quality of the institutions but about the relative seriousness with which the executive branches treat continuity. The Trump administration is treating NSB-vacancy as desired condition; the Starmer government treated JCVI-vacancy as crisis.

The Whitehouse letter from Senator Whitehouse to NSF acting director Granger Morgan, dated April 25 and citing potential antideficiency-act violations in NSF program operations under the disbanded board, remains unanswered. [4] The letter's specific concern is whether NSF is continuing to obligate funds for programs that statutorily require board approval, and whether such obligations would constitute violations under 31 USC 1341. The unanswered letter sits at Day 11 today; no response has been published, no acting board has been seated to provide approvals, and no statutory pathway for routine program approvals has been formally substituted.

The Senate Commerce, Science, and Transportation Committee's January position — characterized in committee press materials as rejecting the Trump budget's "existential threat" to NSF and NIST — pre-dated the NSB disbandment but established the committee's institutional posture. [5] The CRS report on the FY26 NSF appropriation explains the new awards estimate: 10,000 grants supporting roughly 250,000 scientists, postdoctoral researchers, and graduate students across 1,800 institutions. [6] The number is calibrated to maintain the foundation's pre-2024 award rate; below that floor, the merit-review pipeline begins to compromise.

The C&EN write-up of the disbandment frames the issue as crisis. [7] The Science magazine write-up of the Senate panel mark frames the same week as victory. The two outlets are reading two faces of the same agency under two competing institutional registers — congressional appropriations restoring the funding, executive action removing the governance.

Day 11 is the day the Senate floor and the executive disbandment continue to move in opposite directions. The two registers are not yet in legal conflict. They will be the moment any specific NSF program requires board approval and proceeds without one.

-- NORA WHITFIELD, Chicago